Charles River acquires Retrogenix
We are pleased to announce that Retrogenix has been acquired by Charles River Laboratories. Charles River is a leading global CRO providing drug discovery and development services, and this acquisition further strengthens Charles River’s integrated end-to-end solution for therapeutic antibody, and cell and gene therapy discovery and development.
This is a positive and highly strategic move for both Retrogenix and Charles River, and will provide enhanced value to our shared clients. At Retrogenix, we are proud to have built a unique cell solution for receptor identification and off-target assessment of biologic and cell therapies through our cell microarray platform, and are proud of the impact that this has on scientific and drug discovery programmes.
Charles River is a uniquely positioned CRO with an integrated portfolio that spans the drug research process from target discovery through nonclinical development and manufacturing support. Employing 18,000 professionals at over 100 sites worldwide, the company has a strong track record and participated in the development of 80% of the drugs approved by the FDA over the last 3 years.
“We are delighted to add Retrogenix’s highly effective cell screening service to Charles River’s integrated offering. Coupled with our comprehensive drug discovery service portfolio, Retrogenix’s novel cell microarray technology and library of plasma membrane and secreted protein clones will allow us to support our clients by informing early drug discovery efforts and providing preclinical safety assurance.”
Wilbert Frieling, D.V.M.
Corporate Senior Vice President, Global Discovery Services, Charles River
What this means for you
As part of Charles River, we will continue to provide, and develop further, our capabilities, whilst providing our clients with easier access to a wider range of skills and capabilities to support their programmes.
We will continue to operate from our High Peak UK facilities, and there will be no changes to our uniquely skilled workforce. For those currently undertaking or planning projects with Retrogenix, your current business development and scientific contacts will remain the same, and your existing agreements will remain valid. Therefore, our interactions with clients will continue as they are currently.
“Joining Charles River is a very exciting step for Retrogenix, allowing us to integrate into a comprehensive service supporting the entire CRO development pipeline. With Charles River’s support, we are looking forward to accelerating our growth and technological development.”
Dr Jim Freeth
If you have any specific questions in relation to this acquisition, please feel free to contact us.
We are looking forward to continuing our interactions, as part of Charles River.